Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAF vs TDF for HBeAg-Negative Chronic Hepatitis B in China
NCT02836236Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tenofovir alafenamide in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Jun 2015; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02836236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836236.